Time filter

Source Type

Murviel-lès-Montpellier, France

The several options for therapy in breast cancer underline the difficulties to determine the reliable population which can be treated by a specific adjuvant therapy, and the population in which that therapy could generate morbidity, mortality, "medical surcharge" without prognosis improvement. This problem is particularly accurate in node - negative breast cancer patients. Adjuvant therapy has been proved to be more efficient, so a better definition of the prognosis and the response to adjuvant treatments could allow the selection of a sub-group of patients who can be spared chemotherapy. The quantification of the uPA/PAI-1 tumor content is one of the most relevant prognostic factors in this clinical setting. The integration of the uPA/PAI-1 prognostic information gathered in the multidisciplinary medical consensus meetings could be used to select the node-negative good/prognosis population in which chemotherapy could be avoided. This review will focus on the uPA/PAI-1 system, its biological role and its clinical implications in breast oncology. The different ways to analyse the uPA and PAI-1 content in tumor cells will be also presented and commented. ©John Libbey Eurotext. Source

Jacot W.,Service dOncologie | Romieu G.,Service dOncologie | Lamy P.-J.,Laboratoire Of Biologie Specialisee
Imagerie de la Femme | Year: 2011

Breast cancer remains a major public health problem. Even if there is an increase of this cancer curability, mainly related to the advances in screening and adjuvant therapies, metastatic breast cancer remains a lethal disease in the vast majority of cases. Therapeutic advances in the chemotherapy and targeted therapies fields induced an increase in survival, however the proportion of long survivors remains low. One of the putative hypotheses of these results can be in the phenotypic instability of cancer cells, an early process initiated during tumour progression, and metastatic stage of the disease. An increasing amount of scientific data are pledging for a reanalysis of the phenotypic profile of metastatic lesions in order to identify drugable targets and allow individualisation of the treatment of theses metastatic breast cancer patients. This article presents a comprehensive analysis of the frequency of theses phenotypic changes altogether with new modalities to evaluate this phenotypic status. © 2011 Elsevier Masson SAS. All rights reserved. Source

Lamy P.-J.,Laboratoire Of Biologie Specialisee | Roques S.,Laboratoire Of Biologie Specialisee | Viglianti C.,Laboratoire Of Biologie Specialisee | Fabbro M.,Service dOncologie Gynecologique | Montels F.,Laboratoire Of Biologie Specialisee
Annales de Biologie Clinique | Year: 2010

Human epididymis protein 4 (HE4) is a novel marker for ovarian cancer. HE4 exhibits a high sensitivity to detect ovarian cancer and can be used with CA125 as a predictor of malignancy. Additional uses of HE4 are as an aid of monitoring response to therapy for patients with invasive ovarian cancer and as a marker to detect recurrences in the follow-up after treatment of the primary tumor. The HE4 EIA, an enzyme immunoassay for the quantitative determination of HE4 in human serum developed by Fujirebio Diagnostic Inc. (Tokyo, Japan), is now available with a CE-IVD label in Europe (Diasource, Nivelles, Belgium). The aim of the study was to evaluate according to the COFRAC LAB GTA 04 guide, the analytical performance of the test, using 4 standardized samples (target values: 49.8, 140.4, 167.6 and 415.2 pmol/L) and serum samples from patients with ovarian cancer treated in our institution. Intra- and inter-assay precisions showed coefficients of variation less than 10%. The low limit of detection (4 pmol/L) and the limit of quantitation (8 pmol/L) are suitable for clinical samples assessment. The assay mean dilution linearity is 100 ± 10% (90 to 107% of recovery). Globally, the uncertainty varied from 13.1% (low values) to 28.1% (elevated values). We conclude that the HE4 EIA from Fujirebio Diagnostic Inc. displayed convenient analytical performances that allows its use it clinical practice. Source

Discover hidden collaborations